I agree with you, Brandon. We have just been early on this one as we seem to know more than laypersons. For OPTR, it was already run way up in price just before it's PDUFA. I held through the PDUFA on that one and then OPTR was all over the place in price since the approval. If we buy in at these levels there is still much potential to appreciate in price for each new catalyst as you outlined above. I looked at the structures of Zyvox vs. Tedizolid. One striking difference is the amide in Zyvox vs. the primary alcohol in Ted. The alcohol is likely helping to improve pharmaceutical properties in Ted and maybe potency. Also, there are cases where Ted kills Zyvox resistant strains and 6 days vs. 10 days of treatment is also very important, I don't care what anybody else says. All of these factors will help drive the success of Ted in the future.